PubMed ID:
22797645
Public Release Type:
Journal
Publication Year: 2012
Affiliation: UNC Liver Center, Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, NC 27599, USA. mfried@med.unc.edu
DOI:
https://doi.org/10.1001/jama.2012.8265
Authors:
Hoofnagle J,
Navarro V,
Miller C,
Navarro VJ,
Afdhal N,
Afdhal N,
Batey B,
Belle S,
Belle SH,
Blumenthal M,
Bodenheimer HC,
Borg E,
Bowen J,
Colagreco J,
Davis P,
Doo E,
Doo E,
Dougherty KA,
Duffy L,
Elliott S,
Evon D,
Fried MW,
Fried MW,
Gupta D,
Hawke R,
Hawke RL,
Howell M,
Kaplan DE,
Kennedy C,
Kurs-Lasky M,
Laurin J,
Lawlor S,
McFann KK,
Meyers C,
Meyers CM,
Reddy K,
Reddy KR,
Schrieber S,
Seeff L,
Shader RI,
Silymarin in NASH and C Hepatitis (SyNCH) Study Group,
Soule T,
Verma M,
Wahed A,
Wahed AS,
Walton A,
Wirjosemito A,
Zadorozny E
Studies:
Silymarin Trial for Hepatitis C and NASH
The botanical product silymarin, an extract of milk thistle, is commonly used by patients to treat chronic liver disease, despite scant and conflicting evidence of its efficacy.